Immunometabolic endotypes define distinct clinical trajectories in type 2 diabetes.
Vuong BT, Delépine CM, Ratter-Rieck JM, Rinaldi E, Julla JB, Cussenot E, Diedisheim M, Raverdy V, Liu E, Fischer JS, Hepprich M, Alzaid F, Blériot C, Becht E, Cornuot C, de Keizer J, Abdelouahab MB, Chiral M, Pfeil R, Lipaeva P, Dörr D, Zaharia OP, Jolivet T, Alberge J, Potier C, Khider K, Oger F, Riveline JP, Vidal-Trecan T, Tubach F, Estellat C, Abecassis J, Silvin A, Hadjadj S, Varoquaux G, Wagner R, Froguel P, Bonnefond A, Saulnier PJ, Pattou F, Ginhoux F, Roden M, Trombetta M, Potier L, Herder C, Gautier JF, Donath MY, Bonadonna RC, Venteclef N.
Vuong BT, et al. Among authors: saulnier pj.
Cell Metab. 2026 Aug 25:S1550-4131(26)00325-6. doi: 10.1016/j.cmet.2026.07.027. Online ahead of print.
Cell Metab. 2026.
PMID: 42641605